New Treatment Approaches for Acute Myeloid Leukemia with RAS Activation
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation
This project explores new ways to overcome treatment resistance in acute myeloid leukemia (AML) patients whose cancer has a specific genetic change called RAS activation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11122335 on NIH RePORTER |
What this research studies
Many patients with acute myeloid leukemia (AML) have a specific gene change called FLT3, and while treatments exist, the cancer often becomes resistant, especially when another pathway called RAS is also active. This research aims to find new ways to make current AML treatments more effective by focusing on a pathway called RNA Polymerase II. We believe that by targeting this pathway, we can help overcome the resistance that develops in AML cells with RAS activation. Our goal is to identify the most important parts of this pathway and test potential new therapies that could make a difference for patients.
Who could benefit from this research
Good fit: This research is most relevant for patients with acute myeloid leukemia (AML) who have FLT3 mutations and have developed resistance to FLT3 inhibitors, particularly those with RAS pathway activation.
Not a fit: Patients whose AML does not involve FLT3 mutations or RAS pathway activation may not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this work could lead to new treatment options for AML patients who have developed resistance to current therapies due to RAS pathway activation.
How similar studies have performed: This approach builds on preliminary findings that suggest targeting the RNA Polymerase II pathway could help overcome treatment resistance, representing a novel strategy in this specific context.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Smith, Catherine Choy — University of California, San Francisco
- Study coordinator: Smith, Catherine Choy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.